Article
BARD1 and breast cancer genetic predisposition: case-control study and HRD signature analysis.
Breast cancer (Tokyo, Japan) - 1 Sept 2026
Reveneau Marie-Florence, De Pauw Antoine, Masliah-Planchon Julien, Decees Antoine, Lakhlifi Salma, Pasanisi Justine, Gall Jessica Le, Schwartz Mathias, Pagès Mélanie, Pierre-Noël Elise, Sebai Molka, Caputo Sandrine M, Moncoutier Virginie, Tenreiro Henrique, Berthemin Christelle, Carrière Jennifer, Dubois d'Enghien Catherine, Abidallah Khadija, Guy Christophe, Fort Nicolas, Zaguia Narjes, Taribo Anaïs Curto, Grati Olfa Trabelsi, Lori Leslie, Maillard Arnaud, Benoist Camille, Frouin Eleonore, Merchadou Kévin, Quinquis Fabien, Filser Mathilde, Delhomelle Hélène, Le Mentec Marine, Warcoin Mathilde, Bertrand Ophélie, Villy Marie-Charlotte, Saule Claire, Mouret-Fourme Emmanuelle, Gauthier-Villars Marion, Buecher Bruno, Popova Tatiana, Stern Marc-Henri, Renault Victor, Pasmant Eric, Stoppa-Lyonnet Dominique, Colas Chrystelle, Golmard Lisa
Abstract excerpt
INTRODUCTION: BARD1 germline pathogenic variants (gPV) have been primarily associated with moderate breast cancer risk but their rarity limits accurate risk assessment and tailored follow-up guidelines. Our study evaluates the association between BARD1 gPV and breast cancer while exploring the role of BARD1 in mammary oncogenesis. MATERIALS AND METHODS: In this case-control study, 7,309 women with breast cancer...
Topics
Join the communities discussing this publication.